Theriva™ biologics reports full-year 2023 operational highlights and financial results

– the independent data monitoring committee (idmc) recommended the continuation of virage, the phase 2b clinical trial of vcn-01 in combination with chemotherapy for metastatic pancreatic ductal adenocarcinoma (pdac), with no safety concerns raised -

TOVX Ratings Summary

TOVX Quant Ranking